Synaptogenix, Inc., a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced plans to develop Bryostatin-1 for the treatment of multiple sclerosis ("MS"),...
Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to present two posters...
